I am conducting a Risk Assessment on a product containing Carbidopa as DS. In the DP, there are present excipients considered at high-risk for the presence of nitrites (microcristalline cellulose, povidone, magnesium stearate, etc…). Considering that the chemical structure of Carbidopa contains an hydrazine group (with a secondary NH moiety), do you think the product could be at risk for the presence of the relative NSDRI?
Moreover, considering that theoretically CPCA approach cannot be applied (since the n-nitroso group of the N-Nitroso Carbidopa is not bonded to carbon atoms on both sides), which limit should be applied?